Bluejay Diagnostics Q2 EPS $(2.75) Misses $(0.07) Estimate, Cash Balance $5.1M
Portfolio Pulse from Benzinga Newsdesk
Bluejay Diagnostics reported Q2 losses of $(2.75) per share, missing the analyst consensus estimate of $(0.07) by 3828.57 percent. This represents a 2650 percent decrease over losses of $(0.10) per share from the same period last year. The company's cash balance stands at $5.1M.
August 16, 2023 | 11:11 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Bluejay Diagnostics reported significantly higher losses than expected in Q2, which could negatively impact investor sentiment and the company's stock price.
Bluejay Diagnostics reported a much higher loss than expected, missing analyst estimates by a large margin. This could lead to a decrease in investor confidence and a potential drop in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100